Dose-response relationships of sulfonylureas: Will doubling the dose double the response?

Southern Medical Journal

Volumn 100, Issue 11, 2007, Pages 1132-1136

  Rambiritch, Virendra ^a   Naidoo, Poobalan ^b   Butkow, Neil ^b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b NONE

Author keywords

Dose response relationship; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; SULFONYLUREA;

CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCOSYLATION; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; RECOMMENDED DRUG DOSE; REVIEW;

ADMINISTRATION, ORAL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS;

EID: 35948943886     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318158420f     Document Type: Review

References (37)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29:S43-S48.
2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes and its complications. part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
3. DCCT Research Group. The effects of intensive treatment on the development and progression of long-term complications in IDDM. N Engl J Med 1993;329:977-986.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
5. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411.
6. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000;60:95-113.
7. Charbonnel BH, Matthews DR, Schern-Thaner G, et al. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med 2005;22:399-405.
8. Duncan GG, Levin R. Symposium of clinical and experimental effects of sulfonylureas in diabetes mellitus. Metabolism 1956;5:721-726.
9. Kahn CR, Shechter Y. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: A Rall TW Nies AS Taylor P eds. Goodman Gilman, Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th edition. McGraw-Hill, Inc, 1991.
10. Palmer KJ, Brogden RN. Gliclazide: an update of its pharmacological properties and therapeutic efficacy in non-insulin dependent diabetes mellitus. Drugs 1993;46:92-125.
11. Muller G, Satoh Y, Geisen K. Extrapancreatic effects of sulfonylureas-a comparison between glimepiride and conventional sulfonylureas. Diabetes Res Clin Pract 1995;28:115-37.
12. Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycaemia: current ideas on mechanism of impaired glucose-induced insulin secretion. Diabetes Care 1992;15:442-455.
13. Lebovitz H, Melander A. Sulfonylureas: basic aspects and clinical uses. In: Alberti KGMM, Zimmet, P DeFronzo RA, eds. International Textbook of Diabetes Mellitus. 2nd edition. Chichester, Wiley and Sons Ltd, 1997, pp 817-840.
14. Heerdink ER, Erquhart J, Leufkens HG. Changes in prescribed drug doses after market introduction. Pharmacoepidemiol Drug Saf 2002;11:447-453.
15. Wahlin-Boll E, Almer L-O, Melander A. Bioavailability, kinetics and effects of glipizide in type 2 diabetics. Clin Pharmacokinet 1982;7:363-372.
16. Shaw KM, Wheeley MS, Campbell DB, Ward JD. Home blood glucose monitoring in non-insulin-dependent diabetics: the effect of gliclazide on blood glucose and weight control, a multicentre trial. Diabet Med 1985;2:484-490.
17. Jackson L, Robertson L. Sulphonyureas (specifically glibenclamide) and their correct dosage. S Afr Med J 1989;76:286-289.
18. Stenman S, Melander A, Groop P-H, et al. What is the benefit of increasing the sulfonylurea dose? Ann Intern Med 1993;118:169-172.
19. Simonson DC, Kourides IA, Feinglos M, et al. for the glipizide gastrointestinal therapeutic system study group: efficacy, safety, and dose response characteristics of glipizide gastrointestinal therapeutic system on glycaemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997;20:597-606.
20. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
21. Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 2001;3:403-409.
22. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview. Diabetes 2004;53:151-155.
23. Rambiritch V. The pharmacokinetics and pharmacodynamics of glibenclamide in type 2 diabetics. Dissertation. University of KwaZulu-Natal, South Africa. 2004.
24. Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004;26:1714-1727.
25. Groop LC, Groop PH, Stenman S, et al. Comparison of pharmacokinetics, metabolic effects and mechanisms of action of glyburide and glipizide during long-term treatment. Diabetes Care 1987;10:71-78.
26. Groop LC, Barzilai N, Ratheiser K, et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 1991;14:724-727.
27. Herman WH, Fajans SS, Oritz FJ, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994;43:40-46.
28. Naidoo P, Virendra R, Layla M. Effects of gliclazide dose escalation on postprandial hyperglycemia in type 2 diabetes mellitus: A prospective, open-label, case-controlled, dose-escalation study. Curr Ther Res 2006;67:81-102.
29. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003;46:M9-16.
30. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997;20:1822-1826.
31. American Diabetes Association. Clinical practice recommendations 2003. Diabetes Care 2003;26:S1-S156.
32. American College of Endocrinology, American Association of Clinical Endocrinologists. American Diabetes Association: American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract 2002;8:S5-S11.
33. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994;11:223-241.
34. Jonsson A, Rydberg T, Ekberg G, et al. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994;17:142-145.
35. Rydberg T, Jonsson A, Roder M, Melander A. Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 1994;17:1026-1030.
36. Huizar JF, Gonzalez LA, Alderman J, Smith HS. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetes. J Am Coll Cardiol 2003;42:1017-1021.
37. Quast U, Stephan D, Bieger S, Russ U. The impact of ATP-sensitive K+ channel subtypeselectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 2004;53:S156-S164.